These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

839 related items for PubMed ID: 26385220

  • 1. Elevated BLyS levels in patients with systemic lupus erythematosus: Associated factors and responses to belimumab.
    Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D.
    Lupus; 2016 Apr; 25(4):346-54. PubMed ID: 26385220
    [Abstract] [Full Text] [Related]

  • 2. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
    Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW, BLISS-52 and BLISS-76 Study Groups.
    Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
    [Abstract] [Full Text] [Related]

  • 3. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus.
    Doria A, Stohl W, Schwarting A, Okada M, Scheinberg M, van Vollenhoven R, Hammer AE, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2018 Aug 04; 70(8):1256-1264. PubMed ID: 29671280
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 04; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 6. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus.
    Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, Recta V, Zhong J, Freimuth W.
    Arthritis Rheum; 2008 Aug 04; 58(8):2453-9. PubMed ID: 18668552
    [Abstract] [Full Text] [Related]

  • 7. Impact of concomitant medication use on belimumab efficacy and safety in patients with systemic lupus erythematosus.
    Schwarting A, Dooley MA, Roth DA, Edwards L, Thompson A, Wilson B.
    Lupus; 2016 Dec 04; 25(14):1587-1596. PubMed ID: 27488472
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May 04; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 10. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 26; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 11. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar 26; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 12. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.
    van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.
    Ann Rheum Dis; 2012 Aug 26; 71(8):1343-9. PubMed ID: 22337213
    [Abstract] [Full Text] [Related]

  • 13. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N, D'Cruz DP.
    Expert Rev Clin Immunol; 2015 Feb 26; 11(2):195-204. PubMed ID: 25543845
    [Abstract] [Full Text] [Related]

  • 14. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM, BLISS-52 and -76 Study Groups.
    Lupus; 2013 Jan 26; 22(1):63-72. PubMed ID: 23263865
    [Abstract] [Full Text] [Related]

  • 15. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.
    Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW, BLISS-52 Study Group, BLISS-76 Study Group.
    Arthritis Rheum; 2012 Jul 26; 64(7):2328-37. PubMed ID: 22275291
    [Abstract] [Full Text] [Related]

  • 16. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 26; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 17. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.
    Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.
    Arthritis Rheum; 2009 Sep 15; 61(9):1168-78. PubMed ID: 19714604
    [Abstract] [Full Text] [Related]

  • 18. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.
    Lupus; 2018 Aug 15; 27(9):1489-1498. PubMed ID: 29807477
    [Abstract] [Full Text] [Related]

  • 19. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 15; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of belimumab in two serologically distinct high disease activity subgroups of patients with systemic lupus erythematosus: post-hoc analysis of data from the phase III programme.
    Maslen T, Bruce IN, D'Cruz D, Ianosev M, Bass DL, Wilkinson C, Roth DA.
    Lupus Sci Med; 2021 Feb 15; 8(1):. PubMed ID: 33568389
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.